Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Cancer Immunology, Immunotherapy : CII|June 8, 2021
Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinomaWataru Fukuokaya, Takahiro Kimura, Takafumi Yanagisawa, et al.
Targeted Oncology|January 5, 2021
Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial CarcinomaWataru Fukuokaya, Takahiro Kimura, Takafumi Yanagisawa, et al.
The Prostate|August 4, 2019
No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancerMasatoshi Tanaka, Takahiro Kimura, Yumina Iwamura, et al.
BJU International|July 15, 2020
Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumabWataru Fukuokaya, Takahiro Kimura, Takafumi Yanagisawa, et al.
The Prostate|September 24, 2021
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancerTakafumi Yanagisawa, Takahiro Kimura, Keiichiro Mori, et al.
Clinical Genitourinary Cancer|April 4, 2026
Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With DenosumabYuzo Inaba, Fumihiko Urabe, Yu Imai, et al.
Urologic Oncology|October 8, 2025
Predicting recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: Development and validation of the JIKEI-YAYOI scoreYuya Iwamoto, Halle Foss, Yudai Ishiyama, et al.
Japanese Journal of Clinical Oncology|January 25, 2026
Tumor cell invasion of blood vessels predicts poor survival in upper tract urothelial carcinoma following radical nephroureterectomyMiyaka Umemori, Shun Sato, Fumihiko Urabe, et al.
BJU International|July 19, 2025
Clinical features of medication-related osteonecrosis of the jaw in prostate cancer managementYuma Goto, Fumihiko Urabe, Yue Ogihara, et al.
Urologic Oncology|May 19, 2026
Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPCShuhei Hara, Keiichiro Mori, Ryotaro Yamaguchi, et al.
Pageof 3